BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 27178449)

  • 1. Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer.
    Lian Y; Yin H; Pollak MN; Carrier S; Platt RW; Suissa S; Azoulay L
    Eur Urol; 2016 Nov; 70(5):808-815. PubMed ID: 27178449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
    Loeb S; Folkvaljon Y; Lambe M; Robinson D; Garmo H; Ingvar C; Stattin P
    JAMA; 2015 Jun 23-30; 313(24):2449-55. PubMed ID: 26103029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms.
    Shkolyar E; Li S; Tang J; Eisenberg ML
    J Sex Med; 2018 Jul; 15(7):982-989. PubMed ID: 29884444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase Type 5 Inhibitors and Risk of Malignant Melanoma: Matched Cohort Study Using Primary Care Data from the UK Clinical Practice Research Datalink.
    Matthews A; Langan SM; Douglas IJ; Smeeth L; Bhaskaran K
    PLoS Med; 2016 Jun; 13(6):e1002037. PubMed ID: 27299522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between phosphodiesterase type 5 inhibitors use and risk of melanoma: a meta-analysis.
    Deng T; Duan X; Liu B; Lan Y; Cai C; Zhang T; Zhu W; Mai Z; Wu W; Zeng G
    Neoplasma; 2018; 65(2):216-221. PubMed ID: 29534582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase type 5 inhibitors and risk of melanoma: A meta-analysis.
    Tang H; Wu W; Fu S; Zhai S; Song Y; Han J
    J Am Acad Dermatol; 2017 Sep; 77(3):480-488.e9. PubMed ID: 28728871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study.
    Li WQ; Qureshi AA; Robinson KC; Han J
    JAMA Intern Med; 2014 Jun; 174(6):964-70. PubMed ID: 24710960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Health Maintenance Practices and Skin Cancer Risk as a Possible Source of Detection Bias.
    Drucker AM; Li WQ; Savitz DA; Weinstock MA; Han J; Li T; Qureshi AA; Cho E
    JAMA Dermatol; 2019 Mar; 155(3):353-357. PubMed ID: 30586131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skin Cancer Risk in Hematopoietic Stem-Cell Transplant Recipients Compared With Background Population and Renal Transplant Recipients: A Population-Based Cohort Study.
    Omland SH; Gniadecki R; Hædersdal M; Helweg-Larsen J; Omland LH
    JAMA Dermatol; 2016 Feb; 152(2):177-83. PubMed ID: 26454261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. History of Keratinocyte Carcinoma and Risk of Melanoma: A Prospective Cohort Study.
    Wu S; Cho E; Li WQ; Qureshi AA
    J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 28376160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations among rotating night shift work, sleep and skin cancer in Nurses' Health Study II participants.
    Heckman CJ; Kloss JD; Feskanich D; Culnan E; Schernhammer ES
    Occup Environ Med; 2017 Mar; 74(3):169-175. PubMed ID: 27663986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia.
    Velez NF; Karia PS; Vartanov AR; Davids MS; Brown JR; Schmults CD
    JAMA Dermatol; 2014 Mar; 150(3):280-7. PubMed ID: 24429548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma?: A systematic review and meta-analysis.
    Feng S; Zhou L; Liu Q; He Q; Liao B; Wei X; Li H; Wang K; Zhu Y
    Medicine (Baltimore); 2018 Jan; 97(3):e9601. PubMed ID: 29504984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Niacin intake and risk of skin cancer in US women and men.
    Park SM; Li T; Wu S; Li WQ; Weinstock M; Qureshi AA; Cho E
    Int J Cancer; 2017 May; 140(9):2023-2031. PubMed ID: 28152570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.
    Loeb S; Folkvaljon Y; Robinson D; Schlomm T; Garmo H; Stattin P
    Eur Urol; 2016 Nov; 70(5):824-828. PubMed ID: 26743040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial.
    Christian JB; Lapane KL; Hume AL; Eaton CB; Weinstock MA;
    J Natl Cancer Inst; 2008 Sep; 100(17):1223-32. PubMed ID: 18728281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endometriosis and the risk of skin cancer: a prospective cohort study.
    Farland LV; Lorrain S; Missmer SA; Dartois L; Cervenka I; Savoye I; Mesrine S; Boutron-Ruault MC; Kvaskoff M
    Cancer Causes Control; 2017 Oct; 28(10):1011-1019. PubMed ID: 28799019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of skin cancer in patients with pterygium: a nationwide population-based cohort study in Taiwan.
    Yu HC; Lin CL; Chen ZT; Hu FR; Sung FC; Wang IJ
    Ocul Surf; 2014 Jan; 12(1):69-76. PubMed ID: 24439048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The occurrence of non-melanoma malignant skin lesions and non-cutaneous squamous-cell carcinoma among metastatic melanoma patients: an observational cohort study in Denmark.
    Li H; Pedersen L; Nørgaard M; Ulrichsen SP; Thygesen SK; Nelson JJ
    BMC Cancer; 2016 May; 16():295. PubMed ID: 27141983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erectile Dysfunction Medications and Skin Cancer: An Analysis in US Veterans.
    Christie A; Vera PL; Higgins M; Kumar S; Lane M; Preston D
    Urology; 2019 Apr; 126():116-120. PubMed ID: 30735744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.